Literature DB >> 32353170

Cutaneous lesions in a patient with COVID-19: are they related?

B Ahouach1, S Harent2, A Ullmer3, P Martres4, E Bégon1, L Blum1, O Tess5, C Bachmeyer6.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32353170      PMCID: PMC7267646          DOI: 10.1111/bjd.19168

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   11.113


× No keyword cloud information.
Dear Editor, A previously healthy 57‐year‐old woman presented with fever (39 °C) lasting for 4 days, and dry cough and rash appeared 2 days before. Diffuse fixed erythematous blanching maculopapular lesions were present, asymptomatic over the limbs and trunk, with burning sensation over the palms (a, b). She denied any drug intake, excepting paracetamol for fever. Thorax computed tomography scan was typical of COVID‐19; nasopharyngeal swab polymerase chain reaction (PCR) confirmed SARS‐CoV‐2. Infectious enquiry was otherwise negative. Skin biopsy specimen showed slight spongiosis, basal cell vacuolation and mild perivascular lymphocytic infiltrate (c). PCR on whole‐skin biopsy specimen was negative for SARS‐CoV‐2. Fever and rash resolved within 9 days, dry cough within 2 weeks. Urticarial and chilblain‐like lesions have been reported in patients with COVID‐19, but other phenotypes could be observed.1  2 In our patient an immune reaction to the virus is possible.
  2 in total

1.  Two cases of COVID-19 presenting with a clinical picture resembling chilblains: first report from the Middle East.

Authors:  A Alramthan; W Aldaraji
Journal:  Clin Exp Dermatol       Date:  2020-05-24       Impact factor: 3.470

Review 2.  Urticarial eruption in COVID-19 infection.

Authors:  D Henry; M Ackerman; E Sancelme; A Finon; E Esteve
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-06       Impact factor: 9.228

  2 in total
  42 in total

Review 1.  Cutaneous Manifestations in the Context of SARS-CoV-2 Infection (COVID-19).

Authors:  J M Carrascosa; V Morillas; I Bielsa; M Munera-Campos
Journal:  Actas Dermosifiliogr       Date:  2020-10-15

Review 2.  Insights into urticaria in pediatric and adult populations and its management with fexofenadine hydrochloride.

Authors:  Ignacio J Ansotegui; Jonathan A Bernstein; Giorgio W Canonica; Sandra N Gonzalez-Diaz; Bryan L Martin; Mario Morais-Almeida; Margarita Murrieta-Aguttes; Mario Sanchez Borges
Journal:  Allergy Asthma Clin Immunol       Date:  2022-05-13       Impact factor: 3.373

3.  A systematic review of the histopathologic survey on skin biopsies in patients with Corona Virus Disease 2019 (COVID-19) who developed virus or drug-related mucocutaneous manifestations.

Authors:  Niloufar Najar Nobari; Farnoosh Seirafianpour; Milad Dodangeh; Afsaneh Sadeghzadeh-Bazargan; Elham Behrangi; Samaneh Mozafarpoor; Azadeh Goodarzi
Journal:  Exp Dermatol       Date:  2021-05-24       Impact factor: 4.511

Review 4.  A Comprehensive Review of Cutaneous Manifestations Associated with COVID-19.

Authors:  Hoda Rahimi; Zohreh Tehranchinia
Journal:  Biomed Res Int       Date:  2020-07-05       Impact factor: 3.411

Review 5.  Skin disorders associated with the COVID-19 pandemic: A review.

Authors:  Jennifer Akl; Jessica El-Kehdy; Antoine Salloum; Anthony Benedetto; Paula Karam
Journal:  J Cosmet Dermatol       Date:  2021-07-01       Impact factor: 2.189

Review 6.  Cutaneous manifestations of SARS-CoV-2 infection: a clinical update.

Authors:  P Gisondi; S PIaserico; C Bordin; M Alaibac; G Girolomoni; L Naldi
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-07-20       Impact factor: 9.228

Review 7.  Cutaneous manifestations in patients with COVID-19: a preliminary review of an emerging issue.

Authors:  A V Marzano; N Cassano; G Genovese; C Moltrasio; G A Vena
Journal:  Br J Dermatol       Date:  2020-07-05       Impact factor: 11.113

8.  Skin amidst COVID-19 pandemic.

Authors:  Bhavya Swarnkar; Neetu Bhari
Journal:  Dermatol Ther       Date:  2020-08-24       Impact factor: 3.858

Review 9.  Patients with specific skin disorders who are affected by COVID-19: What do experiences say about management strategies? A systematic review.

Authors:  Niloufar Najar Nobari; Azadeh Goodarzi
Journal:  Dermatol Ther       Date:  2020-07-07       Impact factor: 3.858

10.  Herpes zoster in COVID-19-positive patients.

Authors:  Federico Tartari; Alberto Spadotto; Corrado Zengarini; Rossana Zanoni; Alba Guglielmo; Alexander Adorno; Cinzia Valzania; Alessandro Pileri
Journal:  Int J Dermatol       Date:  2020-06-12       Impact factor: 2.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.